antitumo相关论文
Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients wit
Objective: Fluzoparib (SHR3162) is a novel,potent poly(ADP-ribose) polymerases (PARP)1,2 inhibitor that showed anti-tumo......
